S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY
Susan Bal(University of Alabama at Birmingham Hospital), Omar Nadeem(Harvard University), Myo Htut(City Of Hope National Medical Center), Allison Kaeding(Bristol-Myers Squibb (United States)), Daniel Egan, Larry D. Anderson(Dana-Farber Cancer Institute), Kristen Hege(University of California, San Francisco), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Tara Gregory(Colorado Blood Cancer Institute), Jesús G. Berdeja(Tennessee Oncology), Mehmet H. Kocoglu(University of Maryland, Baltimore), Michael R. Burgess(Bristol-Myers Squibb (United States)), Hongxiang Hu(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Luciano J. Costa(University of Alabama at Birmingham), Yanping Chen(Bristol-Myers Squibb (United States)), Lisa M. Kelly(Bristol-Myers Squibb (United States))
Cited by 15
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505